OR WAIT null SECS
This article serves as a landing page for our 3-part series spotlighting how a lack of diversity in clinical trials has had a deleterious downstream effect on real-world care for people of color in the US, with perspective from experts across more than half a dozen specialties.
In medicine, the lack of diversity in clinical trials is the elephant in the room and has been for decades. Despite initiatives and programs geared at improving equity in healthcare, the field still falls short of achieving this goal. To recognize the conclusion of Black History Month, the HCPLive Editorial reached out to expert opinion leaders across an array of specialties for their perspectives on how this lack of clincial trial diversity has impacted real-world care and what the community can do to address this glaring issue.
Part 1: How a Historic Lack of Diversity Manifests in Real-World Care
How has the historical lack of diversity in clinical trials affected your specialty, and what specific challenges has it posed in delivering equitable healthcare outcomes for all patients within your field?
Part 2: How Lack of Trial Diversity Impacts Treatment Development and Application
In your experience, to what degree has the underrepresentation of diverse populations in clinical research impacted the development and application of medical treatments within your discipline?
Part 3: How to Address a Lack of Diversity in Clinical Trials
If the issue of diversity in clinical trials is not adequately addressed, how do you foresee it further influencing the future landscape of your specialty? What steps should be taken to ensure more inclusive and representative research practices for the benefit of diverse patient populations?
Our group of opinion leaders included in this feature includes representatives for the following fields: cardiology, gastroenterology, nephrology, psychiatry, pulmonology, rheumatology, and sleep medicine.
Related Content: